Oct 1 Written by Heajin Kim Heajin Kim Previous Previous Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration Next Next Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer
